Effects of kinesitherapy on chronic non-specific low back pain: discussion based on clinical observations

In chronic nonspecific low back pain (CNLBP), an integrated approach is effective, which must include kinesitherapy. Unfortunately, in our country, kinesitherapy is not always used in CNLBP, ineffective methods of therapy are often used. The article presents an observation of a 55-year-old female patient who suffered from CNLBP. Magnetic resonance imaging of the lumbar spine revealed protrusions up to 4 mm at the level of L4-L5, L5-S1 segments, which were regarded as the cause of back pain. The patient was prescribed non-steroidal anti-inflammatory drugs (NSAIDs), ointments at the place of residence, limitation of physical activity was recommended, which did not have a significant positive effect. In a specialized neurological center, during manual examination, the patient showed signs of lesion of the right sacroiliac joint (SIJ), and with diagnostic and treatment blockade (with anesthetics and corticosteroids) of the right SIJ, an almost complete temporary regression of pain was noted. The patient was explained the causes of pain, the role of SIJ lesions, prolonged physical inactivity and static loads as the causes of CNLBP, the safety and effectiveness of kinesitherapy. Movalis® (meloxicam) was used as an NSAID at 15 mg per day. The patient underwent exercises to activate the gluteal muscles, rectus abdominis muscles, strengthen the back of the thigh, relieve tension from the square muscles of the lower back, and relax the hip flexor muscles. Techniques for controlling the neutral position of the spine and the walking pattern were worked out. Within 10 days, the pain completely disappeared, functional disorders on the Oswestry scale decreased from 34% to 10%. Over the next 3 months, the patient regularly performed therapeutic exercises, avoided static loads, her physical activity increased from 10 to 26 points, back pain did not bother her. The issues of the effectiveness of kinesitherapy in CNLBP are discussed. It is noted that in CNLBP, regularity of physical exercises, exclusion of abrupt and excessive movements, and static loads are of leading importance. Walking represent a highly effective method of treatment and prevention of CNLBP and should be combined with other methods of kinesitherapy. The efficacy and low risk of complications from the use of meloxicam in patients with CNLBP not only from the gastrointestinal tract, but also from the cardiovascular system are noted. The use of kinesitherapy in complex therapy can help many patients with CNLBP, in whom it has not been previously used.

chronic nonspecific lumbar pain, lesions of the sacroiliac joint, kinesitherapy, exercise therapy, nonsteroidal antiinflammatory drugs, meloxicam

1. Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 301 Acute and Chronic Diseases and Injuries in 188 Countries, 1990–2013: A Systematic Analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743–800. doi: 10.1016/s0140-6736(15)60692-4.

2. Maher C., Underwood M., Buchbinder R. Non-specific low back pain. Lancet. 2017;389(10070):736–747. doi: 10.1016/S0140-6736(16)30970-9.

3. Kamper S.J., Apeldoorn A.T., Chiarotto A., Smeets R.J.E.M., Ostelo R.W.J.G., Guzman J., van Tulder M.W. Multidisciplinary Biopsychosocial Rehabilitation for Chronic Low Back Pain: Cochrane Systematic Review and Meta-Analysis. BMJ. 2015;350:h444. doi: 10.1002/14651858.cd000963.pub3.

4. Chou R., Deyo R., Friedly J. Skelly A., Hashimoto R., Weimer M. et al. Nonpharmacologic Therapies for Low Back Pain: A Systematic Review for An American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166(7):493–505. doi: 10.7326/m16-2459.

5. Airaksinen O., Brox J.I., Cedraschi C., Hildebrandt J., Klaber-Moffett J., Kovacs F. et al. Chapter 4 European Guidelines for the Management of Chronic Nonspecific Low Back Pain. Eur Spine J. 2006;15(Suppl. 2):S192S300. doi: 10.1007/s00586-006-1072-1.

6. Koes B.W., van Tulder M., Lin C.-W.C., Macedo L.G., McAuley J., Maher C. An Updated Overview of Clinical Guidelines for the Management of Non-Specific Low Back Pain in Primary Care. Eur Spine J. 2010;19:2075–2094. doi: 10.1007/s00586-010-1502-y.

7. Wong J.J., Côté P., Sutton D.A., Randhawa K., Yu H., Varatharajanet S. et al. Clinical Practice Guidelines for the Noninvasive Management of Low Back Pain: A Systematic Review by the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration. Eur J Pain. 2016;21(2):201–216. doi: 10.1002/ejp.931.

8. Stochkendahl M.J., Kjaer P., Hartvigsen J., Kongsted A., Aaboe J., Andersenet M. et al. National Clinical Guidelines for Non-Surgical Treatment of Patients with Recent Onset Low Back Pain or Lumbar Radiculopathy. Eur Spine J. 2017;27(1):60–75. doi: 10.1007/s00586-017-5099-2.

9. Qaseem A., Wilt T.J., McLean R.M., Forciea M.A. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline from the American College of Physicians. Ann Intern Med. 2017;166(7):514–530. doi: 10.7326/M16-2367.

10. Parfenov V.A., Yakhno N.N., Davydov O.S., Kukushkin M.L., Churyukanov M.V., Golovacheva V.A. et al. Chronic Nonspecific (Musculoskeletal) Low Back Pain. Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2S):7–16. (In Russ.) doi: 10.14412/2074-2711-2019-2S-7-16.

11. Gerasimova O.N., Parfenov V.A., Kalimeeva E.Yu. Treatment of Patients with Acute and Subacute Dorsalgia. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018;10(3):36–41. (In Russ.) doi: 10.14412/2074-2711-2018-3-36-41.

12. Parfenov V.A., Kalimeeva E.Yu., Gerasimova О.N. Management of Patients with Acute Back Pain Now and 10 Years Ago. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):66–71. (In Russ.) doi: 10.14412/2074-2711-2019-1-66-71.

13. Parfenov V.A., Parfenova E.V. Issues of Therapy of Chronic Non-Specific Lumbodynia. Meditsinskiy sovet = Medical Council. 2020;(8):46–52. (In Russ.) doi: 10.21518/2079-701X-2020-8-46-52.

14. Podchufarova Ye.V., Yakhno N.N. Back pain. Moscow: GEHOTAR-Media; 2010. 368 p. (In Russ.).

15. Niederer D., Mueller J. Sustainability Effects of Motor Control Stabilisation Exercises on Pain and Function in Chronic Nonspecific Low Back Pain Patients: A Systematic Review with meta-Analysis and Meta-Regression. PLoS ONE. 2020;15(1):e0227423. doi: 10.1371/journal.pone.0227423.

16. Van Middelkoop M., Rubinstein S.M., Verhagen A.P., Ostelo R.W., Koes B.W., van Tulder M.W. Exercise Therapy for Chronic Nonspecific Low-Back Pain. Best Pract Res Clin Rheumatol. 2010;24(2):193–204. doi: 10.1016/j.berh.2010.01.002.

17. Hayden J.A., Wilson M.N., Stewart S., Cartwright J.L., Smith A.O., Riley R.D. et al. Exercise Treatment Effect Modifiers in Persistent Low Back Pain: An Individual Participant Data Meta-Analysis of 3514 Participants from 27 Randomised Controlled Trials. Br J Sports Med. 2020;54(21):1277–1278. doi: 10.1136/bjsports-2019-101205.

18. Saragiotto B.T., Maher C.G., Yamato T.P., Costa L.O.P., Menezes Costa L.C., Ostelo R.W.J.G., Macedo L.G. Motor Control Exercise for Chronic NonSpecific Low-Back Pain. Cochrane Database Syst Rev. 2016;(1):CD012004. doi: 10.1002/14651858.CD012004.

19. Owen P.J., Miller C.T., Mundellet N.L., Verswijverenal S.J.J.M., Tagliaferri S.D., Brisby H. Which Specific Modes of Exercise Training Are Most Effective for Treating Low Back Pain? Network Meta-Analysis. Br J Sports Med. 2020;54(21):1279–1287. doi: 10.1136/bjsports-2019-100886.

20. O’Connor S.R., Tully M.A., Ryan B., Bleakley C.M., Baxter G.D., Bradley J.M., McDonough S.M. Walking Exercise for Chronic Musculoskeletal Pain: Systematic Review and Meta-Analysis. Arch Phys Med Rehabil. 2015;96(4):724–734.e3. doi: 10.1016/j.apmr.2014.12.003.

21. Kuritzky L., Samraj G.P. Nonsteroidal Anti-Inflammatory Drugs in the Treatment of Low Back Pain. J Pain Res. 2012;5:579–590. doi: 10.1002/14651858.CD000963.pub3.

22. Kamper S.J., Apeldoorn A.T., Chiarotto A., Smeets R.J.E.M., Ostelo R.W.J.G., Guzman J., van Tulder M.W. Non-Steroidal Anti-Inflammatory Drugs for Chronic Low Back Pain. Cochrane Database Syst Rev. 2016;(2):CD012087. doi: 10.1002/14651858.

23. Singh G., Lanes S., Triadafilopoulos S. Risk of Serious Upper Gastrointestinal and Cardiovascular Thromboembolic Complications with Meloxicam. Am J Med. 2004;117:100–106. doi: 10.1016/j.amjmed.2004.03.012.

24. Chen Y.F., Jobanputra P., Barton P., Bryan S., Fry-Smith A., Harris G., Taylor R.S. Cyclooxygenase-2 Selective Non-Steroidal Anti-Inflammatory Drugs (Etodolac, Meloxicam, Celecoxib, Rofecoxib, Etoricoxib, Valdecoxib and Lumiracoxib) for Osteoarthritis and Rheumatoid Arthritis: A Systematic Review and Economic Evaluation. Health Technol Assess. 2008;12(11):1–278, iii. doi: 10.3310/hta12110.

25. Hawkey C., Kahan A., Steinbrück K., Alegre C., Baumelou E., Bégaud B. et al. Gastrointestinal Tolerability of Meloxicam Compared to Diclofenac in Osteoarthritis Patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol. 1998;37(9):937–945. doi: 10.1093/rheumatology/37.9.937.

26. Asghar W., Jamali F. The Effect of COX-2-Selective Meloxicam on the Myocardial, Vascular and Renal Risks: A Systematic Review. Inflammopharmacology. 2015;23(1):1–16. doi: 10.1007/s10787-014-0225-9.

27. Lapi F., Piccinni C., Simonetti M., Levi M., Lora Aprile P., Cricelli I. et al. Non-Steroidal Anti-Inflammatory Drugs and Risk of Cerebrovascular Events in Patients with Osteoarthritis: A Nested Case-Control Study. Intern Emerg Med. 2016;11(1):49–59. doi: 10.1007/s11739-015-1288-3.

28. Dalal D., Dubreuil M., Peloquin C., Neogi T., Zhang Y., Choi H., Felson D. Meloxicam and Risk of Myocardial Infarction: A Population-Based Nested Case-Control Study. Rheumatol Int. 2017;37(12):2071–2078. doi: 10.1007/s00296-017-3835-x.

29. Kang D.O., An H., Park G.U, Yum Y., Park E.J., Park Y. et al. Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction. J Am Coll Cardio 2020;76(5):518–529. doi: 10.1016/j.jacc.2020.06.017.

30. Steffens D., Maher C.G., Pereira L.S., Stevens M.L., Oliveira V.C., Chapple M. et al. Prevention of Low Back Pain: A Systematic Review and Meta-analysis. JAMA Intern Med. 2016;176(2):199–208. doi: 10.1001/jamainternmed.2015.7431.